These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 455822)

  • 1. The effect of hemodialysis on endogenous middle molecules in uremic patients.
    Asaba H; Fürst P; Oulés R; Yahiel V; Zimmerman L; Bergström J
    Clin Nephrol; 1979 May; 11(5):257-66. PubMed ID: 455822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma middle molecules in asymptomatic and "sick" uremic patients.
    Asaba H; Bergström J; Fürst P; Johnson C; Yahiel V
    Artif Organs; 1981; 4 Suppl():137-42. PubMed ID: 7295080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accumulation and excretion of middle molecules.
    Asaba H
    Clin Nephrol; 1983 Mar; 19(3):116-23. PubMed ID: 6839560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of uremic middle molecules in regular hemodialysis patients.
    Asaba H; Alvestrand A; Fürst P; Bergström J
    Clin Nephrol; 1983 Apr; 19(4):179-87. PubMed ID: 6851254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of endogenous middle molecules in normal and uremic body fluids.
    Fürst P; Zimmerman L; Bergström J
    Clin Nephrol; 1976 Apr; 3(2):178-88. PubMed ID: 1277595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Middle molecule accumulation in uremia: an "extra uremic factor".
    Oulès R; Emond C; Claret G; Branger B; Mion H; Mion C
    Artif Organs; 1981; 4 Suppl():177-83. PubMed ID: 7295089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal handling of middle molecules in uremic patients and in the isolated rat kidney.
    Lustenberger N; Schindhelm K; Nordmeyer C; Schurek HJ; Stolte H
    Artif Organs; 1981; 4 Suppl():110-4. PubMed ID: 7295076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uremic middle molecules in non-dialyzed azotemic patients: relation to symptoms and clinical biochemistries.
    Asaba H; Alvestrand A; Bergström J; Fürst P; Yahiel V
    Clin Nephrol; 1982 Feb; 17(2):90-5. PubMed ID: 7067171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uremic middle molecules: separation and quantitation.
    Chapman GV; Farrell PC
    Artif Organs; 1981; 4 Suppl():160-5. PubMed ID: 7295084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uremic middle molecules exist and are biologically active.
    Bergström J; Fürst P; Zimmerman L
    Clin Nephrol; 1979 May; 11(5):229-38. PubMed ID: 455821
    [No Abstract]   [Full Text] [Related]  

  • 12. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
    Lovcić V; Kes P; Zeljko R; Kusec V
    Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Middle molecules in patients with pre-dialysis chronic renal failure: a comparative clearance study.
    Schindhelm K; Lustenberger N; Nordmeyer C; Farrell P; Stolte H
    Clin Nephrol; 1982 Apr; 17(4):200-5. PubMed ID: 7075036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Middle molecules in uremic serum, urine and dialysis fluid.
    Migone L; Dall'taglio P; Buzio C
    Clin Nephrol; 1975; 3(3):82-93. PubMed ID: 1139803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transport of small, middle, and large molecular weight substances in a dual filtration artificial kidney.
    Smeby LC; Jörstad S; Wideröe TE; Svartaas TM
    Artif Organs; 1981; 4 Suppl():104-9. PubMed ID: 7295075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity of middle molecules: clinical evaluation using a selective filtration artificial kidney.
    Jörstad S; Smeby LC; Wideröe TE
    Artif Organs; 1981; 4 Suppl():98-103. PubMed ID: 7295103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of phagocytosis by a middle molecular fraction from ultrafiltrate.
    Ringoir SM; van Landschoot N; de Smet R
    Clin Nephrol; 1980 Mar; 13(3):109-12. PubMed ID: 7379359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of middle molecule compounds.
    Zimmerman L; Jörnvall H; Bergström J; Fürst P; Sjövall J
    Artif Organs; 1981; 4 Suppl():33-6. PubMed ID: 7295092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study.
    Traut M; Haufe CC; Eismann U; Deppisch RM; Stein G; Wolf G
    Blood Purif; 2007; 25(5-6):432-40. PubMed ID: 17957097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dialyzer clearances and mass transfer-area coefficients for small solutes at low dialysate flow rates.
    Leypoldt JK; Kamerath CD; Gilson JF; Friederichs G
    ASAIO J; 2006; 52(4):404-9. PubMed ID: 16883120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.